Activity Report and Sales Note to Accompany Appendix 4C

Melbourne (Australia) – 30th October 2020. Telix Pharmaceuticals provides its Activity Report and Appendix 4C for the quarter ending 30th September 2020, and Q3 2020 sales update for its prostate cancer imaging product.


  • First formal interaction with the U.S. Food and Drug Administration (FDA) on the design of Phase III PROSTACT trial of TLX591 prostate cancer therapeutic product (7th July)
  • Pre-investigational new drug (IND) meeting for TLX591 scheduled with the FDA for 24th November to review final proposed PROSTACT trial design
  • New Drug Application (NDA) for TLX591-CDx prostate cancer imaging product lodged with the FDA (23rd September)

To read the full ASX release please click here.

None of Telix’s product pipeline has received marketing authorization in any jurisdiction.